Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies

被引：0
|
作者：
Deprimo, Samuel E.
Toner, Guy
Mitchell, Paul
De Boer, Richard
Gibbs, Peter
Hicks, Rodney
McArthur, Grant
Brega, Nicoletta
McCarthy, Timothy
Bello, Carlo
机构：
[1] Pfizer Global R&D, La Jolla, CA USA
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Austin Hosp, Melbourne, Vic, Australia
[4] Royal Melbourne Hosp, Melbourne, Vic, Australia
[5] Pfizer Srl, Milan, Italy
[6] Pfizer Inc, Groton, CT 06340 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2910
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies
    Scott, Andrew M.
    Mitchell, Paul L.
    O'Keefe, Graeme
    Saunder, Timothy
    Hicks, Rodney J.
    Poon, Aurora
    Baum, Charles
    Brega, Nicoletta
    McCarthy, Timothy J.
    Toner, Guy C.
    EJNMMI RESEARCH, 2012, 2
  • [42] In-vitro activity of the multi-targeted receptor tyrosine kinase inhibitor sunitinib malate (SU11248) against gastrointestinal stromal tumor (GIST) mutants refractory to imatinib mesylate.
    Prenen, H
    Cools, J
    Mentens, N
    Sciot, R
    Schöffski, P
    van Oosterom, AT
    Marynen, P
    Debiec-Rychter, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9024S - 9024S
  • [43] Population pharmacokinetic (PK)-pharmacodynamic (PD) meta-analysis of sunitinib malate (SU11248) efficacy and tolerability endpoints in gastrointestinal stromal tumor (GIST), metastatic renal cell carcinoma (MRCC) and solid tumor patients.
    Houk, BE
    Bello, C
    Garrett, M
    Poland, B
    Wagg, J
    Wada, R
    Motzer, R
    Rosen, L
    Demetri, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9075S - 9076S
  • [44] A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185
    Biagi, J. J.
    Oza, A. M.
    Grimshaw, R.
    Ellard, S. L.
    Lee, U.
    Sederias, J.
    Ivy, S. P.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
    Fiedler, W
    Serve, H
    Döhner, H
    Schwittay, M
    Ottmann, OG
    O'Farrell, AM
    Bello, CL
    Allred, R
    Manning, WC
    Cherrington, JM
    Louie, SG
    Hong, W
    Brega, NM
    Massimini, G
    Scigalla, P
    Berdel, WE
    Hossfeld, DK
    BLOOD, 2005, 105 (03) : 986 - 993
  • [46] A phase I study of SU11248 in the treatment of patients with acute myeloid leukemia (AML) refractory or resistant or not amenable to conventional therapy.
    Fiedler, W
    Serve, H
    Döhner, H
    Niederwieser, D
    Ottman, OG
    O'Farrell, M
    Bello, C
    Allred, R
    Brega, NM
    Massimini, G
    Scigalla, P
    Berdel, WE
    Hossfeld, DK
    BLOOD, 2003, 102 (11) : 616A - 616A
  • [47] Phase I trial of SU5416, a novel angiogenesis inhibitor, in patients with advanced malignancies
    Rosen, LS
    Kabbinavar, F
    Rosen, P
    Mulay, M
    Quigley, S
    Hannah, AL
    ANNALS OF ONCOLOGY, 1998, 9 : 76 - 76
  • [48] Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST
    Blackstein, M.
    Huang, X.
    Demetri, G. D.
    Casali, P. G.
    Garrett, C. R.
    Schoffski, P.
    Shah, M. H.
    Verweij, J.
    Baum, C. M.
    DePrimo, S. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing
    Blay, J. Y.
    George, S.
    Casali, P. G.
    Le Cesne, A.
    Morgan, J. A.
    Pokela, J.
    Quigley, M. T.
    Tasse, V.
    Baum, C. M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 402 - 402
  • [50] Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061)
    Abdelraouf, Fatma
    Smit, Egbert
    Hasan, Baktiar
    Menis, Jessica
    Popat, Sanjay
    van Meerbeeck, Jan P.
    Surmont, Veerle F.
    Baas, Paul
    O'Brien, Mary
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 35 - 39
12345